Sorry, I was trying to have an actual conversation, but that doesn’t seem to be your intention. Researching penny stock scams doesn’t make you an authority on every early-stage company, especially when you come to a conclusion before considering the full picture. There’s a difference between being cautious and being convinced you’re right regardless of facts, context, or nuance.
If you’ve already decided “this is very clearly one,” then it’s not research you’re doing, it’s confirmation bias. You’re not looking for truth, you’re looking for evidence to support a conclusion you already made. That’s not how real due diligence works.
Early-stage OTC companies are messy, underfunded, and often misunderstood. That doesn’t make them scams, it makes them startups fighting uphill battles without the luxury of institutional backing or mainstream market protection.
So no, “talking” may not change your mind, but facts, execution, and results will. And they won’t be for you, they’ll be for the people who took the time to see the difference between risk and fraud, between struggle and deception, and between building and baiting.
Market Data 
Markets 
AI
